tbuckley/cabot-search huggingface dataset:
Physician Decision Making and Clinical Outcomes With Laboratory Polysomnography or Limited-Channel Sleep Studies for Obstructive Sleep Apnea
Authors: Ching Li Chai-Coetzer, Nick A. Antic, Garun S. Hamilton, Nigel McArdle, Keith Wong, Brendon J. Yee, Aeneas Yeo, Rajeev Ratnavadivel, Matthew T. Naughton, Teanau Roebuck, Richard Woodman, R. Doug McEvoy
Journal: Annals of Internal Medicine (2017)

The clinical utility of limited-channel sleep studies (which are increasingly conducted at home) versus laboratory polysomnography (PSG) for diagnosing obstructive sleep apnea (OSA) is unclear.To compare patient outcomes after PSG versus limited-channel studies.Multicenter, randomized, noninferiority study. (Australian New Zealand Clinical Trials Registry: ACTRN12611000926932).7 academic sleep centers.Patients (n = 406) aged 25 to 80 years with suspected OSA.Sleep study information disclosed to sleep physicians comprised level 1 (L1) PSG data (n = 135); level 3 (L3), which included airflow, thoracoabdominal bands, body position, electrocardiography, and oxygen saturation (n = 136); or level 4 (L4), which included oxygen saturation and heart rate (n = 135).The primary outcome was change in Functional Outcomes of Sleep Questionnaire (FOSQ) score at 4 months. Secondary outcomes included the Epworth Sleepiness Scale (ESS), the Sleep Apnea Symptoms Questionnaire (SASQ), continuous positive airway pressure (CPAP) compliance, and physician decision making.Change in FOSQ score was not inferior for L3 (mean difference [MD], 0.01 [95% CI, -0.47 to 0.49; P = 0.96]) or L4 (MD, -0.46 [CI, -0.94 to 0.02; P = 0.058]) versus L1 (noninferiority margin [NIM], -1.0). Compared with L1, change in ESS score was not inferior for L3 (MD, 0.08 [CI, -0.98 to 1.13; P = 0.89]) but was inconclusive for L4 (MD, 1.30 [CI, 0.26 to 2.35; P = 0.015]) (NIM, 2.0). For L4 versus L1, there was less improvement in SASQ score (-17.8 vs. -24.7; P = 0.018), less CPAP use (4.5 vs. 5.3 hours per night; P = 0.04), and lower physician diagnostic confidence (P = 0.003).Limited-channel studies were simulated by extracting laboratory PSG data and were not done in the home.The results support manually scored L3 testing in routine practice. Poorer outcomes with L4 testing may relate, in part, to reduced physician confidence.National Health and Medical Research Council and Repat Foundation.
Common Polymorphisms of the Interleukin-6 and Chitotriosidase Genes Are Associated with the Risk for Infection with Gram-Negative Bacteria in Children Undergoing Therapy for Acute Myeloid Leukemia.
Authors: Thomas Lehrnbecher, Toralf Bernig, Mitra Hanisch, Ulrike Koehl, Dirk Reinhardt, Ursula Creutzig, Stephen J. Chanock, Thomas Klingebiel, Dirk Schwabe
Journal: Blood (2004)
Effects of MgO modified β-TCP nanoparticles on the microstructure and properties of β-TCP/Mg-Zn-Zr composites
Authors: H.R. Zheng, Z. Li, C. You, D.B. Liu, M.F. Chen
Journal: Bioactive Materials (2017)

The mechanical properties and corrosion resistance of magnesium alloy composites were improved by the addition of MgO surface modified tricalcium phosphate ceramic nanoparticles (m-β-TCP). Mg-3Zn-0.8Zr composites with unmodified (MZZT) and modified (MZZMT) nanoparticles were produced by high shear mixing technology. Effects of MgO m-β-TCP nanoparticles on the microstructure, mechanical properties, electrochemical corrosion properties and cytocompatibility of Mg-Zn-Zr/β-TCP composites were investigated. After hot extrusion deformation and dynamic recrystallization, the grain size of MZZMT was the half size of MZZT and the distribution of m-β-TCP particles in the matrix was more uniform than β-TCP particles. The yield tensile strength (YTS), ultimate tensile strength (UTS), and corrosion potential (Ecorr) of MZZMT were higher than MZZT; the corrosion current density (Icorr) of MZZMT was lower than MZZT. Cell proliferation of co-cultured MZZMT and MZZT composite samples were roughly the same and the cell number at each time point is higher for MZZMT than for MZZT samples.
RETRACTED ARTICLE: Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway
Authors: Jia-Xing Zhang, Yi Xu, Ying Gao, Cui Chen, Zhou-San Zheng, Miao Yun, Hui-Wen Weng, Dan Xie, Sheng Ye
Journal: Molecular Cancer (2017)

Abstract Background The development of chemoresistance and metastasis are the leading causes of death for gastric cancer (GC) patients, however, the molecular mechanisms involved remain unclear. Dysregulation of miRNAs is associated with a variety of disease, including GC. Recently, microarray profiling analysis revealed that miR-939 was dysregulated in human GC samples, but the role of miR-939 in GC has not been intensively investigated. Methods In the present study, we firstly examined the expression pattern of miR-939 in two independent cohorts of clinical GC samples: one cohort of 112 GC patients with stage I-III disease who underwent surgery followed by adjuvant chemotherapy; and another cohort of 110 GC patients with stage IV disease who received palliative chemotherapy. A series of in vivo and in vitro assays were then performed to investigate the function of miR-939 in GC. Results We detected that reduced expression of miR-939 was associated with chemoresistance and increased risk of tumor recurrence in GC patients. Further function study demonstrated that overexpression of miR-939 suppressed GC cell growth, and enhanced 5-fluorouracil-induced chemosensitivity by compromising cellular growth and inducing apoptosis in vitro and in vivo. Moreover, miR-939 repressed the migration and invasion of GC cells in vitro, and diminished the occurrence of lung metastasis in vivo. We further identified solute carrier family 34 member 2 (SLC34A2) was a novel target of miR-939. Mechanistically, we elucidated that miR-939 exerted its function mainly through inhibiting SLC34A2/Raf/MEK/ERK pathway, which is activated in GC. Multivariate analysis identified miR-939, SLC34A2, and their combination as independent indicators for poor prognosis and tumor recurrence in GC patients. Conclusion Our data indicate that miR-939 acts as a tumor suppressor miRNA in GC, and miR-939/SLC34A2 axis represents a novel therapeutic strategy for future GC treatment.
Underperforming Big Ideas in Biomedical Research—Reply
Authors: Michael J. Joyner, Nigel Paneth, John P. A. Ioannidis
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence, risk factors and attenuators of patient-reported concerns among breast cancer survivors.
Authors: Moaath Khader Mustafa Ali, Machelle Moeller, Lisa A. Rybicki, Halle C. F. Moore
Journal: Journal of Clinical Oncology (2016)

10092 Background: Cleveland Clinic breast cancer patients have routinely been offered survivorship visits since 2009. In addition to receiving treatment summaries and follow-up care plans, survivors complete a questionnaire about present concerns and symptoms. It is hypothesized that patient-reported concerns will differ based on treatment received, age, exercise, body mass index (BMI) and timing of survivorship visit. Methods: We conducted a retrospective and prospective IRB-approved cohort study evaluating patient-reported symptoms, comorbidities and associated risk factors at the initial survivorship visit. Patients included had stage 0-III breast cancer, had completed questionnaires and known staging and treatment information. Thirty-four symptoms and comorbidities were analyzed; risk factors were determined using univariable and multivariable logistic regression analyses. Results: Between April 2009 and November 2015, 1126 eligible survivors were seen. Median age was 59 (range 21-93) years. Median time from treatment to survivorship visit was 18 (range 0-300) months. Sixty-six percent of patients were overweight or obese; 52% reported exercising at least 30 minutes most days. All patients had surgery and 64%, 66% and 78% had chemotherapy (CTX), radiotherapy and hormonal therapy respectively. The table demonstrates the most common reported symptoms and significant associations with CTX, BMI and exercise habits using multivariable analyses. Age and time since treatment had variable impact on patient reported concerns. Minimal impact was observed with receipt of radiotherapy or endocrine therapy. Conclusions: In breast cancer survivors, use of chemotherapy and obesity, but not radiation and endocrine therapy, were significantly associated with patient-reported symptoms and comorbidities. Exercise appeared to attenuate the adverse effects. Variable (Prevalence [%]) Exercise Larger BMI Had CTX Hot flashes/night sweats (44) I Paresthesia (34) D I Insomnia (30) I Fatigue (27) D I Concerned about excess weight (26) D I I Problems with sexual activity (24) I Anxiety (24) D I Pain (24) I I Amenorrhea (24) I I: increased symptom prevalence, D: decreased symptom prevalence.
Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients
Authors: Christian Straka, Kerstin Schäfer-Eckart, Florian Bassermann, Bernd Hertenstein, Monika Engelhardt, Hans Salwender, Wolf Rösler, Christian Langer, Georgia Schilling, Stefan Knop, Tim H Brümmendorf, Bernd Metzner, Holger Hebart, Albrecht Reichle, Norbert Frickhofen, Else Heidemann, Juliana Ababei, Christian Gerecke, Wolfram Jung, Martin Gramatzki, Thomas Decker, Martin Kropff, Ralph Naumann, Marcus Hentrich, Jochem Walther, Peter Bojko, Tobias Dechow, Hannes Wandt, Axel Hinke, Hermann Einsele
Journal: Blood (2012)
The MDS-Associated Protein EVI1 Impairs Erythroid and Megakaryocytic Differentiation by Direct Interaction with GATA-1.
Authors: Leopoldo Laricchia-Robbio, Donglan Li, Raffaella Fazzina, Soumen Chakraborty, Maher Abdul Hay, Giuseppina Nucifora
Journal: Blood (2005)
Resource Use and Costs Associated with Routine Management of Febrile Neutropenia in German Hospitals.
Authors: Angela Ihbe-Heffinger, Bernadette Paessens, Volker R. Jacobs, Birgit Ehlken, Margarita Shlaen, Karin Berger, Rudolf Bernard, Christian Peschel, Anita Goertz, Christoph von Schilling
Journal: Blood (2007)
Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.
Authors: Ryan D. Cassaday, Katherine A. Guthrie, Lihua E. Budde, Leslie Thompson, Brian G. Till, Oliver W. Press, Thomas Chauncey, John M. Pagel, Stephen H. Petersdorf, William I. Bensinger, Leona Holmberg, Andrei R. Shustov, Damian J. Green, Edward N. Libby, David G. Maloney, Ajay K. Gopal
Journal: Blood (2012)
Phenotypic Characteristics of Tumor Cells in Patients with Chronic Lymphocytic Leukemia into Different Prognostic Groups
Authors: Aleksei Kuvshinov, Sergei Voloshin, Irina Martynkevich, Ludmila Martynenko, Andrei Garifullin, Elizaveta Kleina, Kudrat Abdulkadyrov
Journal: Blood (2015)
Mechanisms of Increased Reactive Oxygen Species (ROS) Generation Induced by Organic Arsenic Derivative S-Dimethylarsino-Glutathione (SGLU; ZIO-101).
Authors: Xiaodong Cheng, Manshouri Taghi, Peng Huang, Mirna Golemovic, Ralph Zingaro, Emil J. Freireich, Michael Andreeff, Hagop M. Kantarjian, Srdan Verstovsek
Journal: Blood (2005)
The Importance of the Baby-Friendly Hospital Initiative
Authors: Barbara L. Philipp
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
When Deep Blue first defeated Kasparov: is a machine stronger than a radiologist at predicting prognosis in idiopathic pulmonary fibrosis?
Authors: Nicola Sverzellati, Pierre-Yves Brillet
Journal: European Respiratory Journal (2017)

Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive disease with a poor prognosis. Nevertheless, survival time varies substantially, with some patients experiencing an accelerated decline and a few living as long as 10 years after diagnosis [1]. Predicting the future for patients with IPF is challenging. Yet, this is of paramount importance given the clinical implications, such as initiation of treatment, inclusion in clinical trials, referral for lung transplantation or palliation. Quantitative CT data is prognostically more accurate than visual CT scoring in patients with IPF <http://ow.ly/dNMB306gGoR>
ACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI
Authors: Nicholas Blondin
Journal: Neuro-Oncology (2016)

Gliomatosis Cerebri (GC) in adults is a form of infiltrative, diffuse astrocytoma affecting at least three cerebral lobes. It is recognized as a malignant disease with no clear standard of care for treatment, and a poor prognosis for survival. Due to the large volume of treatment, radiation therapy may cause excessive neurological toxicity without a proven survival benefit. Recent data has suggested temozolomide (TMZ) monotherapy may be a safe and effective treatment for adult astrocytoma. Tumor Treating Fields (TTFields) delivered via the Optune device in combination with temozolomide has been proven to extend survival in newly diagnosed glioblastoma patients. Two newly diagnosed GC patients were treated with continuous TTFields therapy and chemotherapy. Patient 1 is a 50 year old man with GC affecting all supratentorial cerebral lobes. Following diagnostic biopsy (astrocytoma WHO Grade 2, IDH-1 mutated) he was treated with continuous TTFields and 12 conventional cycles of TMZ, with a significant radiographic improvement. TTFields were continued beyond 12 months, and at 15 months TMZ was resumed for another 3 cycles. A radiographic progression occurred and he was then treated with continuous TTFields and lomustine/procarbazine for 4 conventional cycles, again with radiographic improvement. His performance status remains excellent. Patient 2 is a 49 year old woman with GC affecting right hemispheric lobes and left frontal lobe. Following diagnostic biopsy (astrocytoma, WHO Grade 2, IDH-1 mutated) she was treated with continuous TTFields and 6 cycles of TMZ, with a significant radiographic improvement. She continued with TTFields therapy for another 6 months and then opted to suspend therapy due to no active disease. The combination of TTFields and chemotherapy, with deferral of radiation therapy, appears to be an effective treatment strategy for newly diagnosed adult GC. A clinical trial in this disease state is warranted.
Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis
Authors: Sayed Mehdi Hamadani, Thomas Samith Kochuparambil, Salman Osman, Ethan Speir, Michael Craig, David Deremer, Aaron Cumpston, Devi D Morrison, Sonia Leadmon, Kristen Sterling, Pamela Bunner, Meghan Sterrett, Vamsi Kota, Anand P. Jillella, Farrukh T Awan
Journal: Blood (2011)
Blood culture-PCR to optimise typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia
Authors: Thomas C. Darton, Liqing Zhou, Christoph J. Blohmke, Claire Jones, Claire S. Waddington, Stephen Baker, Andrew J. Pollard
Journal: Journal of Infection (2017)

BackgroundImproved diagnostics for typhoid are needed; a typhoid controlled human infection model may accelerate their development and translation. Here, we evaluated a blood culture-PCR assay for detecting infection after controlled human infection with S. Typhi and compared test performance with optimally performed blood cultures.Methodology/Principal findingsCulture-PCR amplification of blood samples was performed alongside daily blood culture in 41 participants undergoing typhoid challenge. Study endpoints for typhoid diagnosis (TD) were fever and/or bacteraemia. Overall, 24/41 (59%) participants reached TD, of whom 21/24 (86%) had ≥1 positive blood culture (53/674, 7.9% of all cultures) or 18/24 (75%) had ≥1 positive culture-PCR assay result (57/684, 8.3%). A further five non-bacteraemic participants produced culture-PCR amplicons indicating infection; overall sensitivity/specificity of the assay compared to the study endpoints were 70%/65%. We found no significant difference between blood culture and culture-PCR methods in ability to identify cases (12 mismatching pairs, p = 0.77, binomial test). Clinical and stool culture metadata demonstrated that additional culture-PCR amplification positive individuals likely represented true cases missed by blood culture, suggesting the overall attack rate may be 30/41 (73%) rather than 24/41 (59%). Several participants had positive culture-PCR results soon after ingesting challenge providing new evidence for occurrence of an early primary bacteraemia.Conclusions/SignificanceOverall the culture-PCR assay performed well, identifying extra typhoid cases compared with routine blood culture alone. Despite limitations to widespread field-use, the benefits of increased diagnostic yield, reduced blood volume and faster turn-around-time, suggest that this assay could enhance laboratory typhoid diagnostics in research applications and high-incidence settings.
Modified International Prognostic Score (IPS) for Predicting the Need for Bone Marrow Biopsy (BMB) in Hodgkin's Lymphoma (HL).
Authors: Alaa A Muslimani, Timothy Spiro, Asif A. Chaudhry, Harris C Taylor, Ishmael Jaiyesimi, Praveen Vashist, Hamed A Daw
Journal: Blood (2009)
Genetic Events in Ikaros Gene Family (IKZF1 and IKZF2) in Pediatric T-Cell Lymphoblastic Leukemia/Lymphoma
Authors: Atsushi Narita, Hideki Muramatsu, Nao Yoshida, Hirotoshi Sakaguchi, Sayoko Doisaki, Asahito Hama, Koji Nakanishi, Yoshiyuki Takahashi, Yuji Miyajima, Kimikazu Matsumoto, Koji Kato, Seiji Kojima
Journal: Blood (2012)
Specific Intensive Chemotherapy Plus Rituximab for Advanced Burkitt’s Lymphoma or Leukemia in HIV-Positive and Negative Adult Patients.
Authors: Josep-Maria Ribera, Albert Oriol, Jordi Esteve, Juan Bergua, Santiago Larregla, Salut Brunet, Santiago delPotro, Lourdes Escoda, Maria-Jose Moreno-Rico, Javier Lopez Jimenez, Evarist Feliu
Journal: Blood (2007)
Multiple Myeloma Patients Who Are Chemosensitive and Present with Plasma Cells Lacking Phosphorylated Retinoblastoma and/or Cyclin A Expression Benefit From High Dose Therapy and Autologous Stem Cell Transplantation More.
Authors: Selami Kocak Toprak, Gulsah Kaygusuz, Nazmiye Kursun, Duygu Ozu, Merih Kizil Cakar, Isinsu Kuzu, Meral Beksac
Journal: Blood (2010)
Primary Mediastinal Large B-Cell Lymphoma: A Single Center Experience in Korea.
Authors: Heui June Ahn, Yoo Jin Cho, Myoung Joo Kang, Dae Ro Choi, Shin Kim, Dae Ho Lee, Sang We Kim, Jung Shin Lee, Jooryung Huh, Cheolwon Suh
Journal: Blood (2009)
Splicing Factor 3B Subunit 1 (SF3B1) Mutations Impact FOXP1 Splicing in Chronic Lymphocytic Leukemia (CLL) Cells but Conserve the Balance Between Newly Described and Classical Splicing Variants of ZAP-70
Authors: Herve Roudot, Jennifer Martret, Fanny Baran-Marszak, Jean-Francois Collon, Abdemalek Dahmani, Valerie Lefebvre, Xavier Troussard, Florence Cymbalista, Nadine Varin-Blank, Remi Letestu
Journal: Blood (2015)
In Vitro Assessment of Tolerance and Rejection Occurring After Co-Transplantation of Allogeneic Umbilical Cord Blood and Haploidentical CD34+ Cells as Treatment for Severe Aplastic Anemia
Authors: Nicole J. Gormley, Aleah Smith, Maria Berg, Lisa Cook, Catalina Ramos, Sophia Grasmeder, Theresa Donohue, Richard Childs
Journal: Blood (2010)
Clinical validity of flexible spectral imaging color enhancement (FICE) in small-bowel capsule endoscopy: a systematic review and meta-analysis
Authors: Diana Yung, Pedro Boal Carvalho, Andry Giannakou, Uri Kopylov, Bruno Rosa, Emanuele Rondonotti, Ervin Toth, John Plevris, Anastasios Koulaouzidis
Journal: Endoscopy (2017)

<b>Patients and methods</b> A comprehensive literature search was conducted. We measured pooled rate of lesion visualization improvement and improvement in lesion detection comparing FICE settings 1 – 3 and WLE, for angioectasias and ulcers/erosions. Pooled results were derived using the random-effects model because of high heterogeneity as measured by <i>I</i> <sup>2</sup>. Repeated-measures analysis of variance (ANOVA) was used to measure differences in lesion detection between WLE and the three FICE modes. <b>Results</b> 13 studies were analyzed. All studies used the PillCam SB 1 and/or SB 2 devices. Most used experienced readers. Improvement in delineation had been investigated in 4 studies; in the 3 studies entered into the meta-analysis, using FICE setting 1, 89 % of angioectasias and 45 % of ulcer/erosions were considered to show improved delineation. For FICE settings 2 and 3, small proportions of images showed improved delineation. Heterogeneity of studies was high with <i>I</i> <sup>2</sup> > 90 % in 4/6 analyses. Lesion detection had been investigated in 10 studies; meta-analysis included 5 studies. Lesion detection did not differ significantly between any of the FICE modes and WLE. <b>Conclusions</b> Overall, the use of the three FICE modes did not significantly improve delineation or detection rate in SBCE. In pigmented lesions, FICE setting 1 performed better in lesion delineation and detection.